Princeton University Study Reveals the Crucial Role of DispersinB(R) Substrate to Bacterial Cell Surface Interaction in Biofilm Formation
WINNIPEG, MANITOBA -- (MARKET WIRE) -- 10/13/09 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms is pleased to announce that a recent research publication from Princeton University reveals the genetic basis of poly-Beta-1,6-N-acetylglucosamine (PNAG), the DispersinB® enzyme substrate, based biofilm formation in bacteria. The manuscript appeared in the open-access journal "PLoS Pathogens" (e1000432, Vol. 5:1-16, 2009).
The publication, entitled "Genetic Dissection of an Exogenously Induced Biofilm in Laboratory and Clinical Isolates of E. coli" by Amini, et al., highlights a novel approach to understanding of biofilm molecular biology beyond what is currently known in order to develop effective strategies for controlling biofilms in clinical settings.
"By using a powerful genome-wide technology, we identified the genes and pathways involved in PNAG-based biofilm formation," stated Dr. Saeed Tavazoie, Department of Molecular Biology and Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey. "Our findings revealed that structural interactions between PNAG and bacterial cell surface structures are the crucial determinants of biofilm formation and pathways of acid tolerance, capsule biosynthesis, and regulation of cell morphology modulate this," added Dr. Tavazoie.
Dr. Sri Madhyastha, Vice President-Research & Chief Scientific Officer of Kane Biotech, commented on the findings stating, "Since DispersinB® target PNAG is involved in E. coli biofilm formation, DispersinB® will prevent as well as disperse E. coli biofilms. This is very useful in designing antibiofilm-antimicrobial combination products comprising DispersinB® and antibiotics for making the antibiotic therapies much more effective against highly resistant biofilm forming bacteria such as deadly E. coli O157:H7".
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as medical device and wound associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts: Kane Biotech Inc. Gord Froehlich President & Chief Executive Officer (204) 477-7592 (204) 453-1314 (FAX) ir@kanebiotech.com www.kanebiotech.com
Released October 13, 2009